VERITAC-2 achieved its primary endpoint in the estrogen receptor 1-mutant population, demonstrating statistically significant ...

An experimental breast cancer treatment co-developed by Pfizer and Arvinas significantly improved the time some patients ...

A next-generation treatment for breast cancer from Pfizer Inc. and Arvinas Inc. posted disappointing results in a final-stage ...

Pfizer (NYSE:PFE) and its partner Arvinas (NASDAQ:ARVN) for the experimental breast cancer drug vepdegestrant announced mixed ...

The drug in question, called vepdegestrant, is an oral PROteolysis TArgeting Chimera (PROTAC) ER degrader. The phase 3 study ...

Vepdegestrant did not improve progression-free survival broadly but saw improvements in one specific patient cohort. Arvinas’ ...

Pharma giant Pfizer and Arvinas’s human epidermal growth factor receptor 2 (HER2) negative breast cancer therapy, ...

Trial results show vepdegestrant, a protein-degrading drug Arvinas is developing with Pfizer, improved on fulvestrant in a ...

Arvinas (ARVN) and Pfizer (PFE) announced topline results from the Phase 3 VERITAC-2 clinical trial evaluating vepdegestrant monotherapy versus ...

Arvinas (ARVN) stock faces a downgrade after underwhelming trial data for breast cancer drug vepdegestrant developed with ...

Pfizer paid a whopping $1 billion upfront for rights to vepdegestrant (formerly ARV-4710 in 2021 – consisting of $650 million ...

Arvinas and Pfizer's Phase 3 trial shows vepdegestrant significantly improves progression-free survival in breast cancer patients.